GAROFALO ELIZABETH A. 4

4 · Xenon Pharmaceuticals Inc. · Filed Jun 3, 2026

AI-generated summary of this filing

Updated Jun 4, 2026

Xenon (XENE) Director Elizabeth Garofalo Receives RSUs

What Happened

Elizabeth A. Garofalo, a director of Xenon Pharmaceuticals (XENE), had 2,645 derivative units converted/exercised into common shares on June 1, 2026 (reported as code M). The filing also shows a corresponding disposition entry for 2,645 derivative units at $0.00 on the same date.
On June 3, 2026 she was granted two RSU awards totaling 12,100 RSUs (10,507 and 1,593 RSUs), reported at $0.00 consideration. These new RSUs are awards/contingent rights to receive common shares in the future.

Key Details

Transaction dates & prices:
- 2026-06-01: Exercise/conversion (code M) — 2,645 shares; price reported $0.00.
- 2026-06-01: Disposition line (code M) — 2,645 shares; price $0.00 (filing provides no further explanation for this line beyond the vesting/settlement entries).
- 2026-06-03: Grants/awards (code A) — 10,507 RSUs and 1,593 RSUs; price $0.00.
Shares owned after transaction: Not specified in the information provided in this summary.
Footnotes:
- F1: The 2,645 shares arose from RSUs granted June 5, 2025 that vested 100% on June 1, 2026.
- F2/F3: The June 3 RSU awards vest 100% on the earlier of June 1, 2027 or the day before the 2027 annual meeting; each RSU represents the right to one common share.
Timeliness: Reported period 2026-06-01 and filed 2026-06-03 — appears to be timely.

Context

These entries reflect compensation-related vesting and new RSU grants (not open-market purchases or sales). RSU vesting and grant activity is commonly part of routine executive/director compensation and does not necessarily signal a personal buy/sell decision.
The filing uses code M for conversion/exercise of derivatives (here, conversion/settlement of vested RSUs) and code A for awards/grants. The record includes a disposition line tied to the June 1 activity; the filing does not explain any tax withholding or share-retention details.

Form 4

Period: 2026-06-01

Director

Transactions

Exercise/Conversion
Common Shares
[F1]
2026-06-01+2,645→ 2,645 total
Exercise/Conversion
Restricted Share Units
[F1]
2026-06-01−2,645→ 0 total
→ Common Shares (2,645 underlying)
Award
Share Option (Right to Buy)
[F2]
2026-06-03+10,507→ 10,507 total
Exercise: $53.46Exp: 2036-06-02→ Common Shares (10,507 underlying)
Award
Restricted Share Units
[F3]
2026-06-03+1,593→ 1,593 total
Exercise: $0.00→ Common Shares (1,593 underlying)

Footnotes (3)

[F1]Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
[F2]Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
[F3]Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Signature

/s/ Nathaniel Adams, Attorney-in-fact|2026-06-03

1 file